Corticosteroids (inhaled and/or intranasal) in the treatment of respiratory allergy in children: Safety vs. efficacy

Allergologia et Immunopathologia

Volumn 35, Issue 5, 2007, Pages 197-208

  Rizzo, M C ^a   Solé, Dirceu ^b   Naspitz, C K ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Adverse effects; Asthma; Bioavailability; Children; Corticosteroids; Growth; Inhaled corticosteroids; Rhinitis; Steroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID DERIVATIVE; CYTOKINE; DEXAMETHASONE; FLUTICASONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR BETA; LIGAND; MOMETASONE FUROATE; PLACEBO; TRIAMCINOLONE ACETONIDE;

AIRWAY; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BLEEDING; BLOOD FLOW; BONE DENSITY; COMPARATIVE STUDY; DATA BASE; DISEASE CONTROL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSPHONIA; EMBASE; ENDOCRINE DISEASE; FIRST PASS EFFECT; GENETIC TRANSCRIPTION; GENOME; GLAUCOMA; HOARSENESS; HUMAN; HYPOTHALAMIC PITUITARY ADRENAL AXIS SUPPRESSION; INHALER; LIGAND BINDING; LIVER METABOLISM; LUNG; MEDLINE; PROTEIN EXPRESSION; QUALITY OF LIFE; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT MUCOSA; REVIEW; SIDE EFFECT; SUBCAPSULAR CATARACT; THRUSH; TREATMENT RESPONSE; UPREGULATION;

EID: 35348858320     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1157/13110315     Document Type: Article

References (101)

1. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998;94:557-72.
2. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005 Br J Pharmacol. 2006;148:245-54.
3. Wu B, Li P, Liu Y, Lou Z, Ding Y, Shu C, et al. 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor /Hsp90/immunophilin heterocomplex. Proc Natl Acad Sci USA. 2004;101:8348-53.
4. Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol Chem. 2001;276:29603-10.
5. Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet. 2005;365:801-3.
6. Rodrigo GJ, Rodrigo C. Corticosteroids in the emergency department therapy of adult acute asthma treatment: an evidence-based evaluation. Chest. 2002;121:1977-87.
7. Wanner A, Horvath G, Brieva JL, Kumar SD, Mendes FS. Nongenomic actions of glucocorticoids on the airway vasculature in asthma. Proc Am Thorac Soc. 2004;1:235-8.
8. Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J. 2003;21:989-93.
9. Tillmann HC, Stuck BA, Feuring M, Rossol-Haseroth K, Tran BM, Losel R, et al. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest. 2004;34:63-73.
10. Rodrigo GJ. Rapid Effects of Inhaled Corticosteroids in Acute Asthma. An Evidence-Based Evaluation. Chest. 2006;130:1301-11.
11. Horvath G, Sutto Z, Torbati A, Conner GE, Salathe M, Wanner A. Norepinephrine transported by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003;10:1152-8.
12. Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J. 2006;27:172-87.
13. Rodrigo GJ. Inhaled corticosteroids in the treatment of asthma exacerbations: essential concepts. Arch Bronconeumol. 2006;42:533-40.
14. Karagiannidis C, Akdis M, Holopainen P, Wooley NJ, Hense G, Ruckert B, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114:1425-33.
15. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993;91:97-101.
16. Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiapparino A, Testi R. Once daily intranasal fluticasone propionate (200 mg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol. 1996;98:274-82.
17. Orhan F, Sekerel BE, Adalioglu G, Pinar M, Tuncer A. Effect of nasal triamcinolone acetonide on seasonal variations of bronchial hyperresponsiveness and bronchial inflammation in nonasthmatic children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2004;92:438-45.
18. Pedersen B, Dahl R, Lindqvist N, Mygind N. Nasal inhalation of the glucocorticoid budesonide from a spacer for the treatment of patients with pollen rhinitis and asthma. Allergy. 1990;45:451-6.
19. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002;109:636-42.
20. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol. 1999;104:S144-9.
21. Meltzer EO, Kunjibettu S, Hall N, Wingertzahn MA, Murcia C, Berger W, et al. Efficacy and safety of ciclesonide, 200 μg once daily, for the treatment of perennial allergic rhinitis Ann Allergy Asthma Immunol. 2007;98:175-81.
22. Adams NP, Bestall JC, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. In: The Cochrane library, Issue 1, Chichester, UK: Wiley; 2005.
23. Adams NP, Bestall JC, Jones PW. Budesonide versus placebo for chronic asthma in children and adults, The Cochrane library, Issue 4, Wiley, Chichester, UK; 1999.
24. Adams NP, Bestall JC, Lasserson TJ, Jones PW. Fluticasone versus placebo for chronic asthma in adults and children. In: The Cochrane library, Issue 3, Chichester, UK; Wiley; 2005.
25. Inhalation devices. CMAJ. 2005;173:S39-45.
26. Chrystyn H. Is total particle dose more important than particle distribution? Respir Med. 1997;91:17-9.
27. Teramoto T, Fukao T, Tomita Y, Terauchi Y, Hosoi K, Matsui E, et al. Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system in Japanese children with bronchial asthma. Allergol Int. 2006;55:317-20.
28. Bisgaard H. Delivery of inhaled medication to children. J Asthma. 1997;34:443-67.
29. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165:1377-83.
30. Barnes NC, Hallett C, Harris TA. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998;92:95-104.
31. Chen SH, Yin TJ, Huang JL. An exploration of the skills needed for inhalation therapy in schoolchildren with asthma in Taiwan. Ann Allergy Asthma Immunol. 2002;89:311-5.
32. Interiano B, Guntupalli KK. Metered-dose inhalers. Do health care providers know what to teach? Arch Intern Med. 1993;153:81-5.
33. McCormack PL, Plosker GL Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents. Drugs. 2006;66:1151-68.
34. Leung SY. Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. J Allergy Clin Immunol. 2005;115:989-96.
35. Biberger C. Efficacy and safety of ciclesonide compared with budesonide in asthma patients: a randomized 12-week study [abstract]. Am J Respir Crit Care Med. 2003;167:A771.
36. Buhl R, Vinkler I, Magyar P, Gyori Z, Rybacki C, Middle MV, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther. 2006;19:404-12.
37. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 2005;61:203-8.
38. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45:146-52.
39. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440-6.
40. Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate Clin Ther. 2006;28:319-31.
41. Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am. 1999;5:537-53.
42. Cerasoli F Jr. Developing the ideal inhaled corticosteroid. Chest. 2006;13:54S-64S.
43. Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther. 2001;14:141-7.
44. Wurthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monoproprionate. Biopharm Drug Dispos. 1990;11:381-94.
45. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids - past lessons and future issues. J Allergy Clin Immunol. 2003;112:S1-40.
46. Belvisi MG, Bundschuh DS, Stoeck M, Wicks S, Underwood S, Battram CH, et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther. 2005;314:568-74.
47. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997;52;476-82.
48. Peters SP. Safety of inhaled corticosteroids in the treatment of persistent asthma. J Natl Med Assoc. 2006;98:851-61.
49. Mortimer KJ, Tattersfield AE. Benefit versus risk for oral, inhaled and nasal glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25:523-39.
50. Masoli M, Holt S, Weatherall M. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004;23:552-8.
51. Holt S, Suder A, Weatherall M. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: a meta-analysis. BMJ. 2001;323:253-6.
52. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids - the physician's perception. Chest. 2006;130:41S-53S.
53. Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russel R, Warner JT, et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J. 2002;19:1207-9.
54. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941-55.
55. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med. 1993;329:1703-8.
56. Simons FE. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. J Allergy Clin Immunol. 1998;102:S77-84.
57. Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J. 1997;10:1507-12.
58. Hele DJ, Belvisi MG. Novel therapies for treatment of inflammatory airway disease. Expert Opin Invest Drugs. 2003;12:5-18.
59. Derom E, Van de Velde V, Marissens S, Engelstatter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients. Pulm Pharmacol Ther. 2005;18:328-36
60. Wilson AM, McFarlanane LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic pituitary-adrenal-axis activity. J Allergy Clin Immunol 1998;101:470-4.
61. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90:56-62.
62. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal-axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2004;93:61-7.
63. Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA, Reed KD, et al. Lack of effect of fluticasone propionate aqueous nasal spray on hypothalamic-pituitary-adrenal axisin 2- and 3-year-old patients. Pediatrics. 2003;112:96-100.
64. Leone FT, Fish JE, Szefler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma and Immunology, and American College of Allergy, Asthma, and Immunology. Chest. 2003;124:2329-40.
65. Boulet LP, Giguere MC, Milot J, Brown J. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol. 1994;94:796-803.
66. Agertoft L, Pedersen S. Bone densitometry in children treated for 3-6 years with high inhaled budesonide. Eur Respir J. 1993;6:261S.
67. Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglas B, et al. Bone metabolism in children with asthma treated with beclomethasone dipropionate. J Pediatr. 1993;122:219-26.
68. Bisgaard H, Hermansen MN. Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med. 2006;354:1998-2005.
69. Pedersen S. Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf. 2006;29:599-612.
70. Hopp RJ, Degan JA, Phelan J, Lappe J, Gallagher GC. Cross-sectional study of bone density in asthmatic children. Pediatr Pulmonol. 1995;20:189-92.
71. Visser MJ, van der Veer E, Postma DS, Arends LR, de Vries TW, Brand PL, et al. Side-effects of fluticasone in asthmatic children: no effects after dose reduction. Eur Respir J. 2004;24:420-5.
72. Bielory L, Blaiss M, Fineman SM, Led ford DK, Lieberman P, Simons FE, et al. Concerns about intranasal corticosteroids for over-the-counter use: postion statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy, Asthma Immunol. 2006;96:514-25.
73. Allen DB. Safety of inhaled corticosteroids in children. Pediatr Pulmonol. 2002;33:208-20.
74. Sharek PJ, Bergman DA, Ducharme F. Beclomethasone for asthma in children: effects on linear growth. In: The Cochrane library, Issue 1, Chichester, UK: Wiley; 2006.
75. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics - 2002. J Allergy Clin Immunol. 2002;110:S141-219.
76. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 1994;93:967-76.
77. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-63.
78. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet. 2003;361:1071-6.
79. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in pre-school children at high risk for asthma. N Engl J Med. 2006;354:1985-97.
80. Pedersen S, Garcia ML, Manjra A, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol. 2006;41:954-61.
81. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol. 2005;115:940-5.
82. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105:E22.
83. Leger D, Annesi-Maesano I, Carat F, Rugina M, Chanal I, Pribil C, et al. Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch Intern Med. 2006;66:1744-8.
84. Suratt PM, Barth JT, Diamond R, D'Andrea L, Nikova M, Perriello VA Jr, et al. Reduced time in bed and obstructive sleep-disordered breathing in children are associated with cognitive impairment. Pediatrics. 2007;119:320-9.
85. Shigemitsu H, Afshar K, Nocturnal asthma Curr Opin Pulm Med. 2007;13:49-55.
86. Leung DY, Spahn JD, Szefler SJ. Immunologic basis and management of steroid-resistant asthma. Allergy Asthma Proc. 1999;20:9-14.
87. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol. 2003;178:347-55.
88. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111:3-22.
89. Szefler SJ, Leung DY. Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Eur Respir J. 1997;10:1640-7.
90. Pujols L, Mullol J, Roca-Ferrer J, Torrego A, Xaubet A, Cidlowski JA, et al. Expression of glucocorticoid receptor- and β-isoforms in human cells and tissues. Am J Physiol Cell Physiol. 2002;283:C1324-31.
91. Jenkins BD, Pullen CB, Darimont BD. Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol Metab. 200112:122-6.
92. Hauk PJ, Goleva E, Strickland I, Vottero A, Chrousos GP, Kisich KO, et al. Increased glucocorticoid receptor β expression converts mouse hybridoma cells to a corticosteroid-insensitive phenotype. Am J Respir Cell Mol Biol. 2002;27:361-7.
93. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA. The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action. J Biol Chem. 1999;274:27857-66.
94. Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid insensitive asthma. Am J Respir Crit Care Med. 2006;173:607-16.
95. Leung DYM, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor? J Exp Med. 1997;186:1567-74.
96. Fruchter O, Kino T, Zoumakis E, Alesci S, De Martino M, Chrousos G, et al. The human Glucocorticoid Receptor (GR) Isoform b differentially supresses Gra-Induced transactivation stimulated by synthetic glucocorticoids. J Clin Endocrinol Metab. 2005;90:3505-9.
97. Curran T, Bravo R, Muller R. Transient induction of c-fos and c-myc is an immediate consequence of growth factor stimulation. Cancer Surv. 1985;4:655-81.
98. English M, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002;23:40-5.
99. Sheng M, Dougan ST, McFadden G, Greenberg ME. Calcium and growth factor pathways of c-fos transcriptional activation require distinct upstream regulatory sequences, Mol Cell Biol. 1988;8:2787-96.
100. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4:E131-6.
101. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol. 2004:113:1100-8.